Suriano Ilaria, Frasca Luca, Longo Filippo, Sarubbi Antonio, Tacchi Giovanni, Crucitti Pierfilippo
Department of Thoracic Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Rome, Italy.
PhD Course in Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT), University Tor Vergata, Viale Oxford, 81, 00133 Rome, Italy.
J Clin Med. 2025 Apr 18;14(8):2800. doi: 10.3390/jcm14082800.
: Contrast-enhanced endobronchial ultrasound (CE-EBUS) is a minimally invasive technique that combines traditional endobronchial ultrasound (EBUS) with a contrast agent (sulfur hexafluoride), enhancing the visualization of blood flow in mediastinal and hilar lymph nodes. This study aimed to assess the use of CE-EBUS in patients with advanced neoplasms and hilar or mediastinal lymphadenopathy, particularly to improve diagnostic accuracy and expedite sample collection. : A retrospective observational study was conducted from April 2021 to December 2023, involving 49 patients divided into two groups: EBUS ( = 26) and CE-EBUS ( = 23). Patients had advanced neoplasms with hilar and mediastinal lymphadenopathy, including bulky masses and nodal metastases with central necrosis. In the CE-EBUS group, 4.8 mL of sulfur hexafluoride was administered intravenously. Morphological, echogenic, and vascular characteristics, diagnostic accuracy, sample collection adequacy and molecular testing were compared between the groups. : The diagnostic accuracy in CE-EBUS was similar to EBUS (21 vs. 19 patients), with no significant difference ( = 0.100). However, for patients with bulky masses and necrosis, the molecular assessment rate was significantly higher in the CE-EBUS group (81.8%) compared to the EBUS group (33.3%) ( = 0.014). : CE-EBUS-TBNA could improve the accuracy of molecular assessments in patients with bulky, necrotic lymphadenopathy and could help collect vital neoplastic tissue for molecular testing.
对比增强型支气管内超声（CE-EBUS）是一种微创技术，它将传统支气管内超声（EBUS）与造影剂（六氟化硫）相结合，增强了纵隔和肺门淋巴结内血流的可视化。本研究旨在评估CE-EBUS在晚期肿瘤合并肺门或纵隔淋巴结肿大患者中的应用，特别是为了提高诊断准确性并加快样本采集。：2021年4月至2023年12月进行了一项回顾性观察研究，纳入49例患者，分为两组：EBUS组（n = 26）和CE-EBUS组（n = 23）。患者患有晚期肿瘤并伴有肺门和纵隔淋巴结肿大，包括巨大肿块和伴有中央坏死的淋巴结转移。在CE-EBUS组中，静脉注射4.8 mL六氟化硫。比较两组之间的形态学、回声和血管特征、诊断准确性、样本采集充分性和分子检测情况。：CE-EBUS的诊断准确性与EBUS相似（分别为21例和19例患者），无显著差异（P = 0.100）。然而，对于有巨大肿块和坏死的患者，CE-EBUS组的分子评估率（81.8%）显著高于EBUS组（33.3%）（P = 0.014）。：CE-EBUS-TBNA可以提高巨大坏死性淋巴结病患者分子评估的准确性，并有助于收集重要的肿瘤组织进行分子检测。
